Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Bristol Myers Squibb (BMS) presented new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis. This data adds to the growing amount of evidence proving Deucravacitinib could be a new oral treatment option for moderate to severe plaque psoriasis. Deucravacitinib is currently under regulatory review in multiple regions, including the United States, Europe, and Japan. If approved, it would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved to treat any disease.

Read full press release


Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK